T
Third Harmonic Bio
Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation
About Third Harmonic Bio
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. The company focuses on advancing THB335, a highly selective, oral small molecule wild type KIT inhibitor, aimed at treating chronic urticaria, severe asthma, and other mast cell-mediated inflammatory conditions. Third Harmonic Bio operates within the biopharmaceutical market, primarily serving patients suffering from these chronic conditions. The business model revolves around the research, development, and eventual commercialization of its proprietary treatments. Revenue generation is expected through the successful development and market introduction of its therapeutic products. The company is committed to improving patient outcomes by providing innovative and effective treatment options.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Atlas Venture
OrbiMed
BVF Partners
General Atlantic
RTW Investments
Boxer Capital
Commodore Capital
RA Capital Management
Ajax Health
Deep Track Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Third Harmonic Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Third Harmonic Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.